Skip to content
  • Partnerships
  • News
  • Contact
Fore Biotherapeutics
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
Search
  • Pipeline
  • Science
    • Plixorafenib Program
    • Publications
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Forte Trial
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Partnerships
  • News
  • Contact

FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers


April 25, 2025 1:19 PM EDT

Read More

Press Release Apr 25 2025 FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients Read more
Press Release Mar 31 2025 FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025 Read more
Press Release Feb 13 2025 FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium Read more
Fore Biotherapeutics logo
  • Science
    • Plixorafenib Program
  • Patients
    • Our Science Explained
    • Clinical Trials
    • Expanded Access
  • Company
    • About Us
    • People
    • Leadership
    • Investors
    • Careers
    • Governance
  • Pipeline
  • Partnerships
  • News
  • Contact
  • Visit us on Twitter
  • Visit us on Linked In
©2025 Fore Biotherapeutics US Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy